Literature DB >> 6187698

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants.

J L Maryanski, M Marchand, C Uyttenhove, T Boon.   

Abstract

After mutagenesis of mouse mastocytoma P815, it is possible to obtain variant (tum-) clones that are almost always rejected by syngeneic DBA/2 mice. Most tum- clones express new variant-specific antigens that can be detected by cytolytic T cells (CTL). Occasionally, mice injected with tum- variants eventually develop progressive tumors. Cells from these tumors were analyzed for antigen expression with variant-specific and P815-specific CTL clones. Out of 13 tumors examined, 11 were composed of cells that had clearly lost a variant-specific antigenic determinant. These results indicate that tum- variants induce a specific host rejection response which usually results in complete elimination of the variant cells, but that occasional antigen-loss constitutes an important mechanism of escape. The loss of a variant-specific antigenic determinant from one tum- clone that had escaped rejection allowed the detection of a residual variant-specific determinant. This was demonstrated by isolating a new CTL clone that lysed both the original tum- clone and its antigen-loss variant, but not other P815 targets. Thus, some complex transplantation antigens can be separated into independent determinants by using antigen-loss variants.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6187698     DOI: 10.1002/ijc.2910310119

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

Review 2.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

3.  Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay.

Authors:  T Wölfel; A Van Pel; E De Plaen; C Lurquin; J L Maryanski; T Boon
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

4.  Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A.

Authors:  Pawel Mroz; Fatma Vatansever; Angelika Muchowicz; Michael R Hamblin
Journal:  Cancer Res       Date:  2013-09-26       Impact factor: 12.701

5.  Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.

Authors:  E De Plaen; C Lurquin; A Van Pel; B Mariamé; J P Szikora; T Wölfel; C Sibille; P Chomez; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

6.  Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide.

Authors:  C Sibille; P Chomez; C Wildmann; A Van Pel; E De Plaen; J L Maryanski; V de Bergeyck; T Boon
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

Review 7.  Characterization of gP85gag as an antigen recognized by Moloney leukemia virus-specific cytolytic T cell clones that function in vivo.

Authors:  F A van der Hoorn; T Lahaye; V Müller; M A Ogle; H D Engers
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

8.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.

Authors:  C Uyttenhove; J Maryanski; T Boon
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

Review 9.  Biological basis for increased sensitivity to radiation therapy in HPV-positive head and neck cancers.

Authors:  V Bol; V Grégoire
Journal:  Biomed Res Int       Date:  2014-04-03       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.